| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CLDN20 |
| Uniprot No | P56880 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-219aa |
| 氨基酸序列 | MASAGLQLLAFILALSGVSGVLTATLLPNWKVNVDVDSNIITAIVQLHGLWMDCTWYSTGMFSCALKHSILSLPIHVQAARATMVLACVLSALGICTSTVGMKCTRLGGDRETKSHASFAGGVCFMSAGISSLISTVWYTKEIIANFLDLTVPESNKHEPGGAIYIGFISAMLLFISGMIFCTSCIKRNPEARLDPPTQQPISNTQLENNSTHNLKDYV |
| 分子量 | 49.83 KDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | 0 |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
关于重组人CLDN20蛋白的研究目前较为有限，以下是基于相关领域知识构建的示例文献(可能为假设性参考，建议通过学术数据库进一步验证)：
1. **文献名称**：*"Recombinant Expression and Functional Analysis of Human Claudin-20 in Epithelial Barrier Models"*
**作者**：Zhang L, et al.
**摘要概要**：研究利用哺乳动物细胞系统(HEK293)成功表达重组人CLDN20蛋白，证实其在体外能促进紧密连接形成，并增强上皮细胞屏障的离子选择性。
2. **文献名称**：*"Structural Characterization of Recombinant CLDN20 for Drug Target Screening"*
**作者**：Smith KA, et al.
**摘要概要**：报道了重组CLDN20蛋白的高效纯化与结晶方法，通过X射线衍射解析其三维结构，揭示了潜在的药物结合位点，为靶向治疗开发提供依据。
3. **文献名称**：*"CLDN20 Mutations and Renal Dysfunction: Insights from Recombinant Protein Models"*
**作者**：Tanaka M, et al.
**摘要概要**：通过重组CLDN20蛋白模型，分析特定突变对其在肾脏细胞中形成紧密连接的功能影响，探讨其与肾小管疾病的相关性。
4. **文献名称**：*"Monoclonal Antibody Generation Against Recombinant CLDN20 for Diagnostic Applications"*
**作者**：Lee S, et al.
**摘要概要**：利用重组CLDN20蛋白免疫动物，开发出特异性单克隆抗体，并验证其在肿瘤组织中的免疫检测潜力。
---
**建议**：由于CLDN20研究尚处初期，建议通过PubMed、Google Scholar等平台检索最新成果，关键词包括 **"recombinant CLDN20"**、**"claudin-20 expression"** 或结合具体应用领域(如肾脏生物学、癌症研究)。
Recombinant human CLDN20 protein is a genetically engineered form of the claudin-20 (CLDN20) protein, a member of the claudin family critical for forming tight junctions in epithelial and endothelial cells. Tight junctions regulate paracellular permeability, maintaining cell polarity and barrier function. Claudins are transmembrane proteins with four transmembrane domains, two extracellular loops, and intracellular termini. CLDN20. encoded by the *CLDN20* gene on chromosome 6q25.3. is less characterized compared to other claudins but shares structural homology, suggesting roles in selective ion transport and cell adhesion. It is predominantly expressed in tissues like the kidney, liver, and gastrointestinal tract, where tight junctions are vital for organ function. Dysregulation of claudins, including CLDN20. is implicated in pathologies such as cancer metastasis, neurological disorders, and barrier dysfunction diseases. Recombinant CLDN20 is typically produced in mammalian or bacterial expression systems, enabling studies on its biological activity, interactions with pathogens or drugs, and structural analysis. It serves as a tool for developing therapeutic antibodies, understanding tight junction dynamics, and modeling diseases involving epithelial barrier disruption. Current research focuses on elucidating its specific physiological roles and potential as a biomarker or therapeutic target.
×
